The New York Post recently reported on the results of a small clinical trial at the University of Auckland, published in the journal Neuropharmacology. It found that microdosing with lysergic acid diethylamide (LSD) was “well-tolerated, with no serious adverse reactions” and offered “preliminary evidence supporting the safety and feasibility of treating moderate depression with microdosed LSD.” Montgomery-Åsberg Depression Rating Scale (MADRS) Scores decreased by nearly 60 percent and remained lower for up to six months.

The Evidence Is No Longer Fringe

Clinical trials involving psychedelics to treat various mental health and substance use disorders are not new. Currently, several trials are exploring psilocybin (and its active metabolite, psilocin), LSD, dimethlyltryptamine (DMT), and ibogaine for conditions such as depression, PTSD, alcohol use disorder, addiction, traumatic brain injury, and other mental health issues, all showing promising results.

...read more at cato.org